Biopharmaceutics & Drug Disposition

Cover image for Vol. 36 Issue 1

Edited By: K. Sandy Pang

Impact Factor: 2.178

ISI Journal Citation Reports © Ranking: 2013: 133/256 (Pharmacology & Pharmacy)

Online ISSN: 1099-081X

Author Guidelines

NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement

For additional tools visit Author Resources - an enhanced suite of online tools for Wiley Online Library journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.

Author Guidelines

Manuscript Submission. All papers must be submitted via the online system. Biopharmaceutics & Drug Disposition operates an online submission and peer review system that allows authors to submit articles online and track their progress via a web interface, If Authors are using the system for the first time, Authors must create an account before Authors can submit online.

Organization of the Manuscript

The journal accepts short communications, original research papers, and review articles from the editors or guest editors. The language of the journal is American English. All submissions must have a margin of 2.2 cm all round, and be double-spaced. Illustrations must be on separate sheets, and not be incorporated into the text. All of the article types should follow the instructions described hereafter. Submissions that do not follow the proposed format will not be reviewed. Each manuscript should contain the following text sections: Title page, Running title page, Abstract, Introduction, Material and Methods, Results, Discussion and Conclusion in the order listed. Each section should be titled and begin on a new page. All pages, excluding figure pages, should be numbered consecutively.

  • Title page. The title should be pertinent and descriptive, and the page must list the full title and names and affiliations of all authors. At the bottom of the tile page, include the name(s) of any sponsor(s) of the research contained in the paper, along with grant number(s).
  • Running page title. Provide a short title no more than 60 characters. Give the full address, including e-mail, telephone and fax, of the corresponding author.
  • Abstract page. Supply an abstract of no more than 250 wordsfor all article types. An abstract is a concise summary of the whole paper not just the conclusions, and is understandable without reference to the rest of the paper. It should contain no citation to other published work. Include 3-5 keywords that describe Authors' paper for indexing purposes.
  • Text. The text includes Introduction, Material and Methods, Results, Discussion, and Conclusion.
  • Appendix. Appendices, if present, should come immediately after the main text and before the references.
  • Acknowledgments. The Acknowledgments section is placed at the end of the text. Grant support and personal assistance are noted here.
  • References. References should not exceed 50, and cited by numbers in square brackets and listed at the end of the paper in the order in which they appear in the text. All references must be complete and accurate. Where possible the DOI for the reference should be included at the end of the reference. Online citations should include date of access. Use Index Medicus abbreviations for journal names. . If necessary, cite unpublished or personal work in the text but do not include it in the reference list. References should be listed in the following style:
    1. Aungst BJ, Blake JA, Hussain MA. An in vitro evaluation of metabolism and poor membrane permeation impeding intestinal absorption of leucine enkephalin, and methods to increase adsorption. Biopharm Drug Dispos 2003; 24 : 1-16. DOI:10.1002/bdd.258
    2. Altman DG. Practical Statistics for Medical Research . Chapman & Hall: London, 1991; 36-38.
    3. Smith QR. Quantitation of blood-brain barrier permeability. In Implication of the Blood-Brain Barrier and Its Manipulation , Neuwelt EA (ed). Plenum Medical Book Company: New York, 1989; 85-117.
    4. The Oncology Website.[24 April 1999].
  • Figure legends. The legend page follows immediately after reference pages in the main document.
  • Tables. Tables should be part of the main document and should be placed after the figure legend pages. Do not use excel files for tables for submission.
  • Group all of the above sections into one, main document for submission.
  • Illustrations Do not include figures in the main document. Upload each figure as a separate file in either .tiff or .eps format, with the lead author's name, the figure number at the top of the figure indicated. Compound figures e.g. 1a, b, c should be uploaded as one figure. Tints are not acceptable. Lettering must be of reasonable size that would still be clearly legible upon reduction and consistent within each figure and set of figures. Where a key to symbols is required, please include this in the artwork itself, not in the figure legend. All instructions must be supplied at the correct resolution:
    • Black and white and colour photos - 300 dpi minimum
    • Graphs, drawings, etc - 800 dpi preferred; 600 dpi minimum
    • Combinations of photos and drawings (black and white and colour) - 500 dpi minimum
  • Others. Structural formulae of parent compounds and metabolites should be given; where possible, these should be general formulae with variable groups identified in a legend.

Short Communications

Short communications are intended for the dissemination of the results of studies that are slightly more limited in scope than those warranting a full paper, and should not exceed 1500 words (excluding references) plus a maximum of one figure and/or one table. Short Communications are subject to the same review process as full papers. Short Communications should contain the same sections as full papers. The Results and Discussion sections may be combined.


Contemporary reviews on topics of interest covering more recent aspects of a topic will be published. These may be critical reviews that present the authors' view of the current state of the subject or prospective articles intended to stimulate discussion and research. Manuscripts submitted under this category may be unsolicited or may be invited by the editor.

Post Acceptance

Further Information

Proofs will be sent to the author for checking. This stage is to be used only to correct errors that may have been introduced during the production process. Prompt return of the corrected proofs, preferably within two days of receipt, will minimize the risk of the paper being held over to a later issue. Free access of the final PDF offprint of your article will be available via Author Services only. Please therefore sign up for Author Services if you would like to access your PDF offprint and enjoy the many other benefits the service offers. Further offprints and copies of the journal may be ordered. There is no page charge to authors.

Authors Resources: Manuscript accepted for publication

If so, check out our suite of tools and services for Authors and sign up for:

  • Article Tracking
  • E-mail Publication Alerts
  • Personalization Tools

Accepted Articles

‘Accepted Articles’ have been accepted for publication and undergone full peer review but have not been through the copyediting, typesetting, pagination and proofreading process. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed.


EarlyView is Wiley's exclusive service presenting individual, complete, peer-reviewed articles as soon as they are ready before the release of the compiled print issue.

Cite EarlyView Articles

To link to an article, take the DOI (digital object identifier) and append it to "" as per the following example:
DOI 10.1002/hep.20941, becomes

To include the DOI in a citation to an article, simply append it to the reference as in the following example:
Oestreicher, N., The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma, Cancer 10(1) , pp. 2054 - 2062, DOI: 10.1002/cncr.21464.

For Authors

For additional tools visit Author Resources - an enhanced suite of online tools for Wiley Online Library journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.

File types. Preferred formats for the text and tables of Authors’ manuscript are .doc, .docx, .rtf, .ppt, .xls. LaTeX files may be submitted provided that an .eps or .pdf file is provided in addition to the source files. Figures may be provided in .tiff or .eps format.

Pre-submission English language editing. Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. A list of independent suppliers of editing services can be found at Japanese authors can also find a list of local English improvement services at All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.

Initial Submission

  • Non-LaTeX Users: Upload Authors’ manuscript files and any supplementary material files. At this stage, further source files do not need to be uploaded.
  • LaTeX Users: For reviewing purposes Author should upload a single .pdf (including any supplementary material) that Author have generated from Authors’ source files. Authors must use the File Designation "Main Document" from the dropdown box.

Revision Submission

  • Non-LaTeX Users: Editable source files must be uploaded at this stage. Tables must appear after the reference list, and be incorporated into the main text. Figures should be uploaded as separate figure files.
  • LaTeX Users: When submitting the revision, Authors must still upload a single .pdf that Authors have generated from the now revised source files. Authors must use the File Designation "Main Document" from the dropdown box. In addition Authors must upload the TeX source files. For all Authors’ source files Authors must use the File Designation "Supplemental Material not for review". Previous versions of uploaded documents must be deleted. For the accepted manuscript, Wiley will use the files which Authors have uploaded to typeset the article within a totally digital workflow.
  • Authors are advised to highlight the changes made according to the suggestions of the reviewers in the revised manuscript – show with different color fonts. Authors can load this version after the “unmarked or clean” revised version. The rebuttal should be uploaded as a supplemental file. The ID# and the revision version should be centered in the header (e.g. BDD-00189-R2).

No Color Charges

Biopharmaceutical & Drug Disposition offers authors the opportunity to reproduce color figures in color for free in both online and printed version of the article.


Unless indicated, authors are given 1 to 3 months to resubmit revisions. An extension to deadline must be communicated by the corresponding author for approval to the Editor who is handling the manuscript. If the Author has created the revision or resubmission and the work is in progress but expires prior to the Author submitting the revised paper, s/he must seek extension in writing. There is no mechanism to accept delayed submissions. A lapsed manuscript may be re-submitted to the journal as a new submission. However, the new submission will be subject to a new process of review and cause delay in the review process.


OnlineOpen is available to authors of articles who wish to make their article open access. With OnlineOpen the author, their funding agency, or institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in PubMed Central and PMC mirror sites. In addition to publication online via Wiley Online Library, authors of OnlineOpen articles are permitted to post the final, published PDF of their article on a website, institutional repository, or other free public server, immediately on publication.

Copyright Transfer Agreement

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit:

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit

Conflict of Interest

All authors must declare financial/commercial conflicts of interest. Even if there is none, this should be stated in a separate paragraph following on from the acknowledgements section. This is a mandatory requirement for all articles.

Plagiarism and COPE Membership

Biopharmaceutics and Drug Disposition endorses the COPE (Committee on Publication Ethics) guidelines and will pursue cases of suspected research and publication misconduct (e.g. falsification, fabrication, plagiarism, inappropriate image manipulation, redundant publication). In such cases, the journal will follow the processes set out in by COPE. For more information about COPE please visit the COPE website at